Should This Patient Start a Statin?
Combine Framingham, SCORE2, or QRISK3 with prednisone dose and carotid plaque overrides, then copy or print a clinic handover.
Systemic synovitis accounts for 30.4% of excess cardiovascular events unseen by general-population lipid scores. Recalibrate Framingham, ASCVD, or SCORE2 baseline output with EULAR weighting, prednisone hazard, and carotid plaque rules.
EULAR 1.5x calibration shifts baseline 6.0% to 9.0% (intermediate band). Up to 42% of reclassified RA patients harbor silent carotid plaque.
Uncorrected Framingham and ACC/AHA Pooled Cohort Equations underpredict 28% to 34% of observed 10-year cardiovascular events in rheumatoid arthritis because active inflammation suppresses LDL cholesterol while accelerating arterial plaque. Sources: Crowson et al., Ann Rheum Dis 2018 and Crowson et al., PLOS ONE 2017.
| Population Equation | Observed / Predicted | RA Multiplier | Impact on Statin Eligibility |
|---|---|---|---|
| Framingham Risk Score | Underpredicts 34% | 1.0x (Uncorrected) | Delays primary lipid therapy when DAS28 > 3.2 |
| ACC/AHA Pooled Cohort | Underpredicts 28% | None native | Requires manual inflammatory risk-enhancer override |
| QRISK3 (RA Weighted) | Calibrated 1.04 | Built-in RA hazard | Captures RA diagnosis and steroid exposure directly |
| EULAR + ATACC-RA Rule | Target 0.98 | 1.5x (Universal RA) | Reclassifies 11% of borderline cases into treat tier |
Observed ATACC-RA cardiovascular events diverge above Framingham predictions from Year 3 onward when active synovitis persists.
Combine Framingham, SCORE2, or QRISK3 with prednisone dose and carotid plaque overrides, then copy or print a clinic handover.
Simulate how CRP suppression under MTX, TNFi, and tocilizumab reverses inflammation-driven hypolipidemia.
Screen ORAL Surveillance age and smoking red flags and compare vascular hazard ratios across csDMARDs and biologics.
Evaluate B-mode carotid duplex and Agatston calcium thresholds alongside preserved consortium citations.